Patents by Inventor Charles Blais

Charles Blais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spirotropane compounds
    Patent number: 8124613
    Abstract: Compounds according to formula (I): wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R?1, and R?2 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: February 28, 2012
    Assignee: Virochem Pharma Inc.
    Inventors: Christophe Moinet, Charles Blais, Monica Bubenik, Laval Chan Chun Kong, Marc Courchesne, Oswy Z. Pereira, Réal Denis, Louis Vaillancourt, Constantin G. Yannopoulos
  • Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
    Patent number: 7968595
    Abstract: The present invention is directed to a substituted 4H-chromene represented by the Formula 1R, substantially free from the corresponding (S)-stereoisomer: The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound 1R, substantially free from the corresponding (S)-stereoisomer, also can be used for the treatment of diseases due to overgrowth of vasculature, such as solid tumors and ocular neovascularization.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: June 28, 2011
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, Shailaja Kasibhatla, William D. Kemnitzer, Ben Y. Tseng, Charles Blais, Denis Labrecque, Henriette Gourdeau
  • Spirotropane compounds and methods for the modulation of chemokine receptor activity
    Patent number: 7960403
    Abstract: Compounds according to formula (I): wherein A, R1, R2 and R3 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: June 14, 2011
    Assignee: Virochem Pharma Inc.
    Inventors: Laval Chan Chun Kong, Christophe Moinet, Marc Courchesne, Louis Vaillancourt, Charles Blais, Monica Bubenik
  • Novel Spirotropane Compounds and Methods for the Modulation of Chemokine Receptor Activity
    Publication number: 20080267906
    Abstract: Compounds according to formula (I): wherein A, R1, R2 and R3 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
    Type: Application
    Filed: December 9, 2005
    Publication date: October 30, 2008
    Inventors: Laval Chan Chun Kong, Christophe Moinet, Marc Courchesne, Louis Vaillancourt, Charles Blais, Monica Bubenik
  • Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
    Publication number: 20080085328
    Abstract: The present invention is directed to a substituted 4H-chromene represented by the Formula 1R, substantially free from the corresponding (S)-stereoisomer: The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound 1R, substantially free from the corresponding (S)-stereoisomer, also can be used for the treatment of diseases due to overgrowth of vasculature, such as solid tumors and ocular neovascularization.
    Type: Application
    Filed: July 6, 2007
    Publication date: April 10, 2008
    Inventors: Sui Xiong Cai, John A. Drewe, Shailaja Kasibhatla, William E. Kemnitzer, Ben Y. Tseng, Charles Blais, Denis Labrecque, Henriette Gourdeau